A rare healthcare issue both parties agree on: A solution to Alzheimer’s that can’t wait

AI Summary

Bipartisan lawmakers introduced the ASAP Act to allow Medicare coverage of FDA-approved blood-based biomarker tests for early detection of Alzheimer's disease and other dementias. The proposal aims to improve access to diagnostic testing.

Bipartisan legislators introduced the ASAP Act to authorize Medicare coverage for FDA-approved blood-based biomarker tests aimed at the early detection of Alzheimer's and other dementias.